{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:27:52Z","timestamp":1785407272970,"version":"3.56.0"},"reference-count":21,"publisher":"Norwegian Medical Association","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.19.0162","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T09:16:56Z","timestamp":1569489416000},"source":"Crossref","is-referenced-by-count":5,"title":["Naloxone nasal spray \u2013 bioavailability and absorption pattern in a phase 1 study"],"prefix":"10.4045","volume":"139","author":[{"given":"Ida","family":"Tylleskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne Kristian","family":"Skulberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turid","family":"Nilsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sissel","family":"Skarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Dale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"ref=1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2016: Trends and Developments. Luxembourg: Publications Office of the European Union, 2016. http:\/\/www.drugsandalcohol.ie\/25579\/1\/Final_EDR_report.pdf Lest\u00a019.6.2019."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Rudd\u00a0RA, Seth\u00a0P, David\u00a0F et al. Increases in drug and opioid-involved overdose deaths - United States, 2010\u20132015. MMWR Morb Mortal Wkly Rep 2016; 65: 1445\u201352. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28033313&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.15585%2Fmmwr.mm655051e1","DOI":"10.15585\/mmwr.mm655051e1"},{"key":"ref=3","unstructured":"Oslo universitetssykehus. Tiltaksbok ambulanse. Opiatoverdose."},{"key":"ref=4","unstructured":"Helse Midt-Norge. Felles retningslinjer ambulanse Midt-Norge: Naloxon."},{"key":"ref=5","unstructured":"Midling AS. N\u00e5 skal norsk nesespray redde liv i tolv land. Forskning.no 26.6.2018. https:\/\/web.archive.org\/web\/20190618103133\/https:\/\/forskning.no\/partner-rus-og-avhengighet-alkohol-og-narkotika\/na-skal-norsk-nesespray-redde-liv-i-tolv-land\/1192214 Lest\u00a018.6.2019."},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Strang\u00a0J, Darke\u00a0S, Hall\u00a0W et al. Heroin overdose: the case for take-home naloxone. BMJ 1996; 312: 1435\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8664611&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fbmj.312.7044.1435","DOI":"10.1136\/bmj.312.7044.1435"},{"key":"ref=7","unstructured":"Nasjonal overdosestrategi 2014\u20132017. Ja visst kan du bli rusfri \u2013 men f\u00f8rst m\u00e5 du overleve. IS-0418. Oslo: Helsedirektoratet, 2014. https:\/\/www.regjeringen.no\/contentassets\/43121155483947d79316af20c68e6d7d\/overdosestrategi_230414.pdf Lest\u00a019.6.2019."},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Dowling\u00a0J, Isbister\u00a0GK, Kirkpatrick\u00a0CM et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008; 30: 490\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18641540&dopt=Abstract","DOI":"10.1097\/FTD.0b013e3181816214"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"McDonald R, Danielsson Glende \u00d8, Dale O et al. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. Drug alcohol rev 2018; 37: 205\u201315.","DOI":"10.1111\/dar.12571"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Strang\u00a0J, McDonald\u00a0R, Tas\u00a0B et al. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? Addiction 2016; 111: 574\u201382. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26840916&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fadd.13209","DOI":"10.1111\/add.13209"},{"key":"ref=11","unstructured":"Hertz S. Naloxone for outpatient use: Data required to support an NDA. U.S. Food and Drug Administration, 2012. https:\/\/web.archive.org\/web\/20161024174802\/http:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM300874.pdf Lest\u00a019.6.2019."},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Tylleskar\u00a0I, Skulberg\u00a0AK, Nilsen\u00a0T et al. Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol 2017; 73: 555\u201362. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28144724&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00228-016-2191-1","DOI":"10.1007\/s00228-016-2191-1"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"McDonald\u00a0R, Lorch\u00a0U, Woodward\u00a0J et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction 2018; 113: 484\u201393. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29143400&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fadd.14033","DOI":"10.1111\/add.14033"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Skulberg\u00a0AK, \u00c5sberg\u00a0A, Khiabani\u00a0HZ et al. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. Addiction 2019; 114: 859\u201367. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30644628&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fadd.14552","DOI":"10.1111\/add.14552"},{"key":"ref=15","unstructured":"NARCAN\u00ae (naloxone hydrochloride) nasal spray \u2013 Prescribing Information, 2017. https:\/\/web.archive.org\/web\/20190618112914\/https:\/\/s3-us-west-2.amazonaws.com\/narcan-assets-uswest\/NARCAN-Prescribing-Information.pdf Lest\u00a018.6.2019."},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Skulberg\u00a0AK, Tylleskar\u00a0I, Nilsen\u00a0T et al. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. Eur J Clin Pharmacol 2018; 74: 873\u201383. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29568976&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00228-018-2443-3","DOI":"10.1007\/s00228-018-2443-3"},{"key":"ref=17","unstructured":"Evzio \u2013 Prescribing Information. 2016. https:\/\/web.archive.org\/web\/20190618114658\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209862lbl.pdf Lest\u00a018.6.2019."},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Neale\u00a0J, Strang\u00a0J. Naloxone\u2013does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin\/opioid overdose. Addiction 2015; 110: 1644\u201352. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26119038&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fadd.13027","DOI":"10.1111\/add.13027"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Tylleskar\u00a0I, Skulberg\u00a0AK, Skarra\u00a0S et al. Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil. Eur J Clin Pharmacol 2018; 74: 1547\u201353. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30143830&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00228-018-2545-y","DOI":"10.1007\/s00228-018-2545-y"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Yassen\u00a0A, Olofsen\u00a0E, van Dorp\u00a0E et al. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. Clin Pharmacokinet 2007; 46: 965\u201380. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17922561&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165%2F00003088-200746110-00004","DOI":"10.2165\/00003088-200746110-00004"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Olofsen\u00a0E, van Dorp\u00a0E, Teppema\u00a0L et al. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology 2010; 112: 1417\u201327. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20461002&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FALN.0b013e3181d5e29d","DOI":"10.1097\/ALN.0b013e3181d5e29d"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Naloksonnesespray \u2013 biotilgjengelighet og opptaksm\u00f8nster i en fase 1-studie"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:36:42Z","timestamp":1781703402000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2019\/09\/originalartikkel\/naloksonnesespray-biotilgjengelighet-og-opptaksmonster-i-en-fase-1-studie"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":21,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2019,9,24]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.19.0162","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]}}}